Increased phosphorylation of Akt in triple-negative breast cancers

被引:56
|
作者
Umemura, Shinobu [1 ]
Yoshida, Sei
Ohta, Yoshikazu
Naito, Kenichiro
Osamura, R. Yoshiyuki
Tokuda, Yutaka
机构
[1] Tokai Univ, Sch Med, Dept Pathol, Kanagawa 2591100, Japan
[2] Tokai Univ, Sch Med, Dept Surg, Kanagawa 2591100, Japan
[3] Takeda Pharmaceut Co, Pharmaceut Res Labs 2, Osaka 5328686, Japan
关键词
D O I
10.1111/j.1349-7006.2007.00622.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cells from breast cancers lacking hormone receptors (estrogen receptor [ER], progesterone receptor [PgR]) and human epidermal growth factor receptor (HER) 2 strongly express the cell proliferation marker Ki-67. However, the mechanisms of and stimulus signals involved in cell proliferation of this type of breast cancer are not well understood. The aim of the present study was to examine the characteristics of signal transduction in triple-negative (ER-, PgR-, and HER2-negative) breast cancers. For 44 tumor samples, western blotting analysis was conducted to examine the phosphorylation of HER2, external signal-regulated kinase (ERK)1 and -2 and Akt, and the immunohistochemical phenotypes of the samples with respect to ER and HER2 were also assessed. Phosphorylation of HER2 was detected in 4 of 15 immunohistochemically HER2-positive tumor samples (26.7%). ERK1/2 was more highly phosphorylated in triple-negative breast cancers. Phosphorylation of Akt kinase was significantly higher in triple-negative breast cancers. Triple-negative breast cancers are characterized by increased phosphorylation of Akt kinase. In the present study, we found for the first time that there is a population with a significantly activated Akt pathway in this type of breast cancer.
引用
收藏
页码:1889 / 1892
页数:4
相关论文
共 50 条
  • [1] Triple-negative breast cancers
    Narod, Steven A.
    Dent, Rebecca
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (10) : 1041 - 1043
  • [2] The Omics of Triple-Negative Breast Cancers
    Xu, Hong
    Eirew, Peter
    Mullaly, Sarah C.
    Aparicio, Samuel
    [J]. CLINICAL CHEMISTRY, 2014, 60 (01) : 122 - 133
  • [3] Molecular Stratification of Triple-Negative Breast Cancers
    Perou, Charles M.
    [J]. ONCOLOGIST, 2010, 15 : 39 - 48
  • [4] Clinicopathological characteristics of triple-negative breast cancers
    Yuka Sasaki
    Hitoshi Tsuda
    [J]. Breast Cancer, 2009, 16 : 254 - 259
  • [5] How basal are triple-negative breast cancers?
    Bertucci, Francois
    Finetti, Pascal
    Cervera, Nathalie
    Esterni, Benjamin
    Hermitte, Fabienne
    Viens, Patrice
    Birnbaum, Daniel
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (01) : 236 - 240
  • [6] Clinicopathological characteristics of triple-negative breast cancers
    Sasaki, Yuka
    Tsuda, Hitoshi
    [J]. BREAST CANCER, 2009, 16 (04) : 254 - 259
  • [7] Molecular Stratification of Triple-Negative Breast Cancers
    Perou, Charles M.
    [J]. ONCOLOGIST, 2011, 16 : 61 - 70
  • [8] Triple-negative breast cancers: Biomarkers and outcomes
    Malorni, L.
    Shetty, P. B.
    Hilsenbeck, S. G.
    Rimawl, M. F.
    Elledge, R. M.
    De Angelis, C.
    Osborne, C. K.
    De Placido, S.
    Arpino, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Adjuvant treatments for triple-negative breast cancers
    Joensuu, H.
    Gligorov, J.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 40 - 45
  • [10] Triple Negative Breast Cancer: prognosis of triple-negative breast cancers and non-triple-negative breast cancers in a large registry of certified breast units
    Kern, P.
    Rezai, M.
    [J]. CANCER RESEARCH, 2012, 72